MicroRNAs in stress signaling and human disease

By Joshua T. Mendell, E. Olson. Cell, 2012

1,718 citations recorded by the source corpus.

Summary Disease is often the result of an aberrant or inadequate response to physiologic and pathophysiologic stress. Studies over the last 10 years have uncovered a recurring paradigm in which microRNAs (miRNAs) regulate cellular behavior under these conditions, suggesting an especially significant role for these small RNAs in pathologic settings. Here, we review emerging principles of miRNA regulation of stress signaling pathways and apply these concepts to our understanding of the roles of miRNAs in disease. These discussions further highlight the unique challenges and opportunities associated with the mechanistic dissection of miRNA functions and the development of miRNA-based therapeutics.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/23f351ad464c6adf6e1b728a470cd8d9f3d2795b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Metazoan MicroRNAs (2018, background): “Indeed, as might be expected for transcription factors or any other component of these networks, deletion of miRNAs can reduce tolerance to environmental challenges, genetic perturbations, injury, or disease (Ebert and Sharp, 2012; Mendell and Olson, 2012; Cassidy et al., 2016; Kasper et al., 2017) ”
Non-coding RNAs in disease: from mechanisms to therapeutics (2023, neutral): “Because their regulatory functions are crucial for normal cell activities, it is not surprising that dysregulation of ncRNAs leads to human disease 8,98 .”
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ (2014, background): “Therefore, miRNAs are proposed to be critical regulators in stress signal mediation and modulation, where inadequate miRNA levels and responses can cause or exacerbate disease (Mendell and Olson, 2012).”
Development of microRNA therapeutics is coming of age (2014, positive): “Recent work has shown that miRNAs are frequently deregulated in human diseases, suggesting that they could serve as viable targets for development of miRNA-based therapeutics (Mendell & Olson, 2012; van Rooij, 2012; van Rooij & Olson, 2012; Stenvang et al , 2012; Thorsen et al , 2012) (Table 1).”